Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43977   clinical trials with a EudraCT protocol, of which   7312   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    980 result(s) found. Displaying page 1 of 49.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-001363-27 Sponsor Protocol Number: DAY101-002 Start Date*: 2023-01-18
    Sponsor Name:Day One Biopharmaceuticals, Inc. (Day One)
    Full Title: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activati...
    Medical condition: Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) IE (Ongoing) HU (Ongoing) DE (Restarted) NO (Ongoing) BE (Ongoing) FI (Ongoing) AT (Ongoing) SI (Ongoing) GR (Ongoing) DK (Ongoing) CZ (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000803-20 Sponsor Protocol Number: C1071006 Start Date*: 2022-11-02
    Sponsor Name:Pfizer Inc.
    Full Title: MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENA...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) ES (Restarted) CZ (Ongoing) BE (Ongoing) DE (Ongoing) FI (Ongoing) HU (Ongoing) FR (Ongoing) GR (Ongoing) DK (Ongoing) AT (Ongoing) IT (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002766-39 Sponsor Protocol Number: ET13-002 Start Date*: 2021-02-17
    Sponsor Name:Centre Leon Berard
    Full Title: SIOP Ependymoma II - An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma
    Medical condition: Newly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellular, papillary, myxopapillary, clear-cell and tanycytic) or anaplastic ependymoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014967 Ependymoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) IE (Ongoing) IT (Ongoing) BE (Ongoing) ES (Ongoing) NO (Ongoing) DE (Ongoing) DK (Restarted) FI (Ongoing) CZ (Ongoing) AT (Ongoing) NL (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001489-17 Sponsor Protocol Number: SIOPENRNET003 Start Date*: 2006-11-17
    Sponsor Name:St. Anna Kinderkrebsforschung e.V.
    Full Title: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
    Medical condition: High Risk Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Ongoing) DK (Restarted) IE (Ongoing) HU (Ongoing) FI (Ongoing) SI (Completed) PL (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002769-44 Sponsor Protocol Number: ESAP Start Date*: 2015-09-28
    Sponsor Name:Medical University of Graz
    Full Title: Efficacy and safety of an accelerated outpatient protocol for hymenoptera venom immunotherapy
    Medical condition: Immunotherapy against systemic anaphylactic sting reactions
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021428 - Immune system disorders 10001749 Allergy to sting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2018-000624-33 Sponsor Protocol Number: HO156_AMLSG28/18 Start Date*: 2019-08-01
    Sponsor Name:HOVON Foundation
    Full Title: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with ne...
    Medical condition: Previously untreated Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001941 AML LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Restarted) LT (Ongoing) BE (Ongoing) FI (Temporarily Halted) FR (Ongoing) IE (Restarted) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003342-25 Sponsor Protocol Number: P170604J Start Date*: 2018-09-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis
    Medical condition: Patients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076654 Cancer-associated thrombosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Temporarily Halted) PL (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Ongoing) GR (Completed) AT (Ongoing) NL (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2013-004187-56 Sponsor Protocol Number: HIT-HGG-2013 Start Date*: 2017-04-24
    Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen
    Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ...
    Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years.
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066254 Gliomatosis cerebri PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060971 Astrocytoma malignant PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017701 Ganglioglioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018340 Gliosarcoma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Restarted) AT (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003526-88 Sponsor Protocol Number: CZAR-1 Start Date*: 2020-12-15
    Sponsor Name:University Hospital Ulm
    Full Title: Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1)
    Medical condition: Waldenström's Macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047801 Waldenstrom's macroglobulinaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) GR (Ongoing) AT (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005078-70 Sponsor Protocol Number: ACTICCA-1 Start Date*: 2014-01-16
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) ...
    Medical condition: Cholangiocarcinoma and gallbladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017620 Gallbladder carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) NL (Ongoing) GB (GB - no longer in EU/EEA) DK (Completed) AT (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002176-41 Sponsor Protocol Number: 17HH4268 Start Date*: 2019-09-03
    Sponsor Name:Imperial College of Science Technology and Medicine
    Full Title: PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)
    Medical condition: Ischaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    20.0 100000004849 10034039 Paroxysmal atrial fibrillation LLT
    20.0 100000004849 10066551 Chronic atrial fibrillation LLT
    20.0 100000004849 10071668 Permanent atrial fibrillation LLT
    22.1 100000004852 10057613 Thromboembolic stroke LLT
    21.1 100000004852 10022754 Intracerebral hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) ES (Ongoing) AT (Ongoing) FR (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002195-13 Sponsor Protocol Number: CNTO1959CRD3001 Start Date*: 2019-06-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Seve...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Restarted) BE (Ongoing) AT (Completed) LT (Completed) CZ (Ongoing) SK (Ongoing) NL (Ongoing) LV (Ongoing) ES (Ongoing) PL (Ongoing) GR (Temporarily Halted) PT (Restarted) HR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003032-22 Sponsor Protocol Number: ALL-SCT-ped-FORUM Start Date*: 2013-02-04
    Sponsor Name:St. Anna Kinderkrebsforschung GmbH
    Full Title: Allogenic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia - FORUM
    Medical condition: acute lymphoblastic leukaemia
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) DE (Restarted) NO (Ongoing) FI (Ongoing) DK (Ongoing) CZ (Completed) NL (Ongoing) SE (Ongoing) IT (Ongoing) BE (Ongoing) ES (Ongoing) SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002162-30 Sponsor Protocol Number: HC-G-H-1504 Start Date*: 2017-04-12
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: Prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution in patients u...
    Medical condition: Hypovolaemia due to acute blood loss in elective abdominal surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10021137 Hypovolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed) ES (Restarted) FR (Ongoing) AT (Completed) HR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-004978-27 Sponsor Protocol Number: 1-2006 Start Date*: 2007-08-03
    Sponsor Name:Zentralklinikum St. Pölten
    Full Title: Initial Combination of Photodynamic Therapy with Verteporfin and Intravitreal Administration of Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation due to Age-related Macular Degene...
    Medical condition: The case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne) for the treatment of subfoveal CNV s...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003351-37 Sponsor Protocol Number: I4V-MC-JAJA Start Date*: 2019-08-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) NL (Trial now transitioned) HU (Completed) DE (Restarted) GR (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000240-34 Sponsor Protocol Number: REX-001-004 Start Date*: 2016-07-07
    Sponsor Name:Rexgenero Limited
    Full Title: The Efficacy and Safety of Intra-Arterial Administration of Rexmyelocel T to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus: A Multicenter, Randomized, Double-Blind, Placebo Contro...
    Medical condition: Critical Limb Ischemia in patients with Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10077142 Limb ischemia LLT
    19.0 100000004866 10058069 Critical limb ischemia LLT
    19.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) AT (Completed) NL (Ongoing) HU (Ongoing) PL (Temporarily Halted) PT (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-011186-88 Sponsor Protocol Number: ABB-09-001 Start Date*: 2009-09-08
    Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
    Full Title: Desarrollo de inhibidores en pacientes no tratados previamente (PUP) o en pacientes mínimamente tratados con componentes sanguíneos (MBCTP) al ser expuestos a concentrados de derivados plasmáticos ...
    Medical condition: El estudio es un ensayo clínico abierto, aleatorizado, controlado, prospectivo, multicéntrico, internacional e independiente sobre la frecuencia de formación de inhibidores en pacientes no tratados...
    Disease: Version SOC Term Classification Code Term Level
    9 10018937 Haemophilia A LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: ES (Prematurely Ended) IT (Completed) PT (Completed) FR (Ongoing) DE (Restarted) AT (Prematurely Ended) BE (Ongoing) GB (GB - no longer in EU/EEA) SK (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003767-25 Sponsor Protocol Number: APL2-C3G-310 Start Date*: 2022-03-08
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolif...
    Medical condition: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    21.1 10038359 - Renal and urinary disorders 10027168 Membranoproliferative glomerulonephritis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Restarted) CZ (Completed) BE (Completed) AT (Ongoing) FR (Ongoing) PL (Completed) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005098-19 Sponsor Protocol Number: 1414-ROG-GUCG Start Date*: 2017-09-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localiz...
    Medical condition: very high risk localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Ongoing) ES (Restarted) FR (Completed) AT (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) DK (Completed) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 27 07:55:31 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA